Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
Status:
Completed
Trial end date:
2018-01-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive
brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive
matched placebo with TACE therapy.